Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286328 | 1.00 | HTR6 (0.48) | HTR6LMNASMN1; SMN2AKR1C3AKR1C1 | |
| SCHEMBL6287562 | 0.88 | HTR6 (0.46) | HTR6LMNASMN1; SMN2FABP4PLK1 | |
| SCHEMBL6287560 | 0.88 | HTR6 (0.46) | HTR6LMNASMN1; SMN2FABP4PLK1 | |
| SCHEMBL6283832 | 0.85 | AKR1C3 (0.60) | HTR6LMNASMN1; SMN2AKR1C3AKR1C1 | |
| SCHEMBL6283829 | 0.85 | AKR1C3 (0.60) | HTR6LMNASMN1; SMN2AKR1C3AKR1C1 | |
| SCHEMBL6286909 | 0.85 | LMNA (0.60) | HTR6LMNASMN1; SMN2AKR1C3AKR1C1 | |
| SCHEMBL6286906 | 0.85 | LMNA (0.60) | HTR6LMNASMN1; SMN2AKR1C3AKR1C1 | |
| SCHEMBL6286249 | 0.84 | CA2 (0.44) | HTR6LMNASMN1; SMN2FABP4PLK1 | |
| SCHEMBL6286245 | 0.84 | CA2 (0.44) | HTR6LMNASMN1; SMN2FABP4PLK1 | |
| SCHEMBL6284744 | 0.83 | HTR3A (0.43) | HTR6LMNASMN1; SMN2AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906095-B2 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002527-A1 | Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2A | HTR6 1/4885LMNA 4212/4885SMN1; SMN2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.